Drugs / QH104
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06018363 | Jun 2023 → Dec 2027 expected | brain glioma, glioblastoma | Dushu Lake Hospital Affiliated to Soochow University | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06592092 | Apr 2024 → May 2025 | neoplastic meningitis | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QH104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06018363 ↗ |
| Modality | Cell therapy | “Allogeneic B7-H3 CAR-γδT Cell Therapy” NCT06018363 ↗ |
| Route | Intrathecal | “intrathecal administration” NCT06018363 ↗ |